BNC Korea Co., Ltd.

A256840

KR7256840000

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
6,200 ^KRW	+0.32%		-2.52%	+67.57%

Mar. 25	Hankook Korus Pharm Co., Ltd. announced that it has received KRW 2 billion in funding from BNC Korea Co., Ltd.	CI
2023	NovMetaPharma Co., Ltd. announced that it has received KRW 6.99999258 billion in funding from BNC Korea Co., Ltd.	CI

BNC Korea Co., Ltd. announced that it has received KRW 40.000011929 billion in funding from a group of investors

April 18, 2021

On April 19, 2021, BNC Korea Co., Ltd. (KOSDAQ:A256840) closed the transaction. The company issued common shares for proceeds of KRW 5,000,011,929 in its second and final tranche closing.

Latest news about BNC Korea Co., Ltd.

Hankook Korus Pharm Co., Ltd. announced that it has received KRW 2 billion in funding from BNC Korea Co., Ltd.	Mar. 24	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 6.99999258 billion in funding from BNC Korea Co., Ltd.	23-06-28	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 6.99999258 billion in funding from BNC Korea Co., Ltd.	23-06-20	CI
BNC Korea Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
BNC Korea Co., Ltd. agreed to acquire a 63.2% stake in Dong-in Biotech Co., Ltd. from Jo Gil-nam and others for KRW 12 billion.	22-05-12	CI
Clips Co., Ltd. announced that it expects to receive KRW 2.50003 billion in funding from EuBiologics Co., Ltd., SK bioscience Co.,Ltd., BNC Korea Co., Ltd.	22-01-26	CI
BNC Korea Co., Ltd.(KOSDAQ:A256840) added to S&P Global BMI Index	21-09-20	CI
BNC Korea Co., Ltd. announced that it has received KRW 40.000011929 billion in funding from a group of investors	21-04-18	CI
BNC Korea Co., Ltd. announced that it expects to receive KRW 40.000011929 billion in funding from a group of investors	21-04-08	CI
BNC Korea Co., Ltd completed the acquisition of NH Special Purpose Acquisition 11 Co., Ltd. in a reverse merger transaction.	19-11-14	CI
BNC Korea Co., Ltd. entered into an agreement to acquire NH Special Purpose Acquisition 11 Co., Ltd. in a reverse merger transaction.	19-06-02	CI
Myfirstasset Asset Management Co., Ltd acquired 4.4% stake in BNC Korea Co.,Ltd. from 2010 KIF-Premier Fund, fund managed by Premier Partners, LLC for KRW 2.5 billion.	18-08-01	CI
NH Investment and Mirae Asset acquired 2.21% stake in BNC Korea Co.,Ltd. from Doo-Yeong Shin for KRW 1.2 billion.	18-01-29	CI
Kolon 2015 Secondary Market, a fund of Kolon Investment, Inc. acquired 2.21% stake in BNC Korea Co.,Ltd from 2010 KIF-Premiere Investment Union for KRW 1.5 billion.	16-03-01	CI

BNC Korea Co. Ltd, formerly NH Special Purpose Acquisition 11 Co., Ltd., is a Korea-based company principally engaged in the manufacture and sale of biopharmaceuticals. The Company's main products include hyaluronic acid (HA) fillers, collagen wound dressings, antiadhesion materials and collagen tissue supplements, and others. In addition, the Company produces and sells cosmetics, medicines and medical devices, among others.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
BNC KOREA CO., LTD.	+67.57%	299M
CSL LIMITED	-4.66%	87.53B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	40.42B
BIOGEN INC.	-19.27%	29.48B
UCB	+57.86%	25.43B
INCYTE CORPORATION	-17.69%	11.49B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.3B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.1B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.75B
INNOVENT BIOLOGICS, INC.	-8.42%	7.99B

Biopharmaceuticals

BNC Korea Co., Ltd.

Equities

A256840

KR7256840000

Pharmaceuticals

BNC Korea Co., Ltd. announced that it has received KRW 40.000011929 billion in funding from a group of investors

Latest news about BNC Korea Co., Ltd.

Chart BNC Korea Co., Ltd.

Company Profile

Income Statement Evolution

Chiffre d''affaires - Rate of surprise

Sector Biopharmaceuticals